Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106781 | 0.79 | BCHE (0.50) | BCHEACHEHSD17B10ALDH1A1CYP1A2 | |
| SCHEMBL21013298 | 0.74 | KDM1A (0.51) | ACHEHSD17B10ALDH1A1CYP1A2HPGD | |
| SCHEMBL9105665 | 0.73 | ACHE (0.62) | BCHEACHEKDM1AMAPK1 | |
| SCHEMBL9749136 | 0.70 | CYP1A2 (0.51) | ACHEALDH1A1CYP1A2 | |
| SCHEMBL5824154 | 0.70 | ALDH1A1 (0.49) | BCHEACHEHSD17B10ALDH1A1CYP1A2 | |
| SCHEMBL21743201 | 0.70 | HSD17B10 (0.55) | BCHEACHEHSD17B10ALDH1A1CYP1A2 | |
| SCHEMBL5410460 | 0.68 | KDM1A (0.66) | ACHEHSD17B10ALDH1A1HPGDNUDT1 | |
| SCHEMBL8781805 | 0.68 | ACHE (0.45) | ACHEALDH1A1CYP1A2KDM1A | |
| SCHEMBL22853896 | 0.67 | KDM1A (0.44) | ACHEHSD17B10ALDH1A1CYP1A2HPGD | |
| SCHEMBL5824150 | 0.67 | ALDH1A1 (0.49) | BCHEACHEHSD17B10ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | BCHE 119/4885ACHE 197/4885HSD17B10 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.